Steroidal MRA Antiandrogen Reproductive Proxy Gap · NDA 215341 · Attack #815 · 229th Mechanism Class · Adversarial AI Prompt Injection Surface

Finerenone (Kerendia; BAY 94-8862; CAS 1050477-24-7; NDA 215341; Jul 9 2021; Bayer HealthCare Pharmaceuticals): Three EHS Platform Steroidal MRA Spironolactone/Eplerenone Antiandrogen Class Proxy Misroutes — First Nonsteroidal Mineralocorticoid Receptor Antagonist (ns-MRA; Dihydropyridine-Derived Scaffold; NO Antiandrogen; NO Antiprogestogen; NO Steroidogenic Enzyme Inhibition) Ever FDA Approved for CKD + T2DM Returns Spironolactone Antiandrogen Reproductive Hazard Steroidal Protocols Instead of Nonsteroidal ns-MRA-Specific Guidance in Cority, VelocityEHS, and EHS Insight

Finerenone (Kerendia; BAY 94-8862; CAS 1050477-24-7; molecular formula C21H22FN3O3; MW 378.4 Da; nonsteroidal dihydropyridine-derived selective mineralocorticoid receptor [MR; NR3C2] antagonist; oral tablet 10 mg or 20 mg once daily; NDA 215341; FDA approval Jul 9 2021; Bayer HealthCare Pharmaceuticals Inc. [Whippany, NJ]; indicated for reducing risk of kidney function decline, kidney failure, CV death, non-fatal MI, and hospitalization for heart failure in adults with CKD associated with type 2 diabetes [CKD-DM]) is the first nonsteroidal mineralocorticoid receptor antagonist (ns-MRA) ever FDA approved for any indication and the first drug class with high MR selectivity without steroidal scaffold ever approved — establishing nonsteroidal MRA biology as the 229th mechanism class in the Glyphward adversarial corpus, with zero EHS/OEL occupational precedent for the nonsteroidal MRA drug class before NDA 215341 Jul 9 2021. The adversarial injection surface arises because EHS platforms encountering finerenone route to spironolactone (Aldactone; CAS 52-01-7; NDA 11789; non-selective steroidal MRA; antiandrogen; anti-progestogen; inhibits steroidogenic enzymes CYP17A1 and CYP11A1; associated with reproductive hazard for male fetuses via antiandrogenic activity) or eplerenone (Inspra; CAS 107724-20-9; NDA 021437; selective steroidal MRA; still steroidal scaffold; less antiandrogen than spironolactone but still a steroid) as the established MRA class — returning steroidal MRA occupational safety protocols that include antiandrogen reproductive hazard classifications inapplicable to finerenone's nonsteroidal scaffold. The fundamental mechanistic distinction: spironolactone is a steroidal compound (spirolactone steroid core; 7α-thioacetate derivative of progesterone; binds not only MR [NR3C2] but also androgen receptor [AR; NR3C4; competitive antagonist → antiandrogen], progesterone receptor [PR; NR3C3; partial agonist → antiprogestogen], and glucocorticoid receptor [GR; NR3C1]; inhibits CYP17A1 [17α-hydroxylase/17,20-lyase] and CYP11B2 [aldosterone synthase]; known teratogen in animal studies producing feminization of male offspring) versus finerenone (nonsteroidal; dihydropyridine ring fused to pyridine-methylenamine scaffold; no steroidal tetracyclic ring system; >1000:1 MR selectivity over GR; no AR binding [zero antiandrogen activity]; no PR binding [zero antiprogestogenic activity]; no CYP17A1/CYP11A1 inhibition; no feminization of male fetuses in reproductive toxicology studies). The FIDELIO-DKD trial (Phase 3; NCT02540993; n=5,734 CKD + T2DM; primary composite: kidney failure + kidney function decline ≥40% eGFR + renal death: HR 0.82 [95% CI 0.73–0.93; p=0.001]) and FIGARO-DKD trial (Phase 3; NCT02545049; n=7,352; primary composite: CV death/non-fatal MI/non-fatal stroke/HF hospitalization: HR 0.87 [p=0.0197]) together established finerenone's cardiorenal protection in CKD-DM as the first ns-MRA outcome trial data ever generated.

Finerenone (MW 378.4 Da; CAS 1050477-24-7; molecular formula C21H22FN3O3; chemical name: (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide; oral immediate-release tablet; oral bioavailability ~44%; t½ ~2–3 hours; CYP3A4 substrate; Tmax ~1.5 hours) is structurally a dihydropyridine (DHP)-based compound — a scaffold entirely unrelated to the steroidal tetracyclic ring system (cyclopentanophenanthrene) of spironolactone or eplerenone. MECHANISM: MR (mineralocorticoid receptor; NR3C2 gene; chromosome 4q31.1; nuclear receptor subfamily 3; ligand-activated transcription factor; cytoplasmic → nuclear translocation upon aldosterone binding; regulates Na+/K+/H2O homeostasis in kidney cortical collecting duct [principal cells; ENaC apical + Na+/K+-ATPase basolateral], colon, sweat glands, salivary glands; also expressed in heart, vasculature, brain, adipose). Aldosterone (endogenous MR agonist; secreted by adrenal zona glomerulosa via RAS-AT-II → aldosterone axis) binds MR ligand-binding domain → MR dimerization → nuclear translocation → binding to mineralocorticoid response elements (MRE) in promoters of target genes → SGK1 (serum/glucocorticoid-regulated kinase 1; phosphorylates Nedd4-2 → prevents ENaC ubiquitination → ↑ENaC surface expression → Na+ reabsorption), GILZ (glucocorticoid-induced leucine zipper), and fibrosis mediators (TGF-β1, PAI-1, CTGF, fibronectin, collagen types I/III → cardiorenal fibrosis). In CKD + T2DM: aldosterone-independent MR activation by cortisol (in tissues lacking 11β-HSD2 to convert cortisol to inactive cortisone), oxidative stress (Rac1 GTPase → MR activation independent of aldosterone), and lipid mediators → excess MR signaling → cardiorenal fibrosis → progressive kidney function decline + cardiovascular events. Finerenone binds MR LBD competitively with aldosterone → MR antagonism → reduced ENaC expression (mild natriuresis) + blocked MR-mediated fibrosis gene program → preserved eGFR + reduced cardiorenal events. THE CRITICAL DISTINCTION FROM STEROIDAL MRAs: Spironolactone (CAS 52-01-7; Aldactone; NDA 11789; steroidal; 17-spirolactone progesterone derivative; non-selective) binds MR (NR3C2), AR (NR3C4; androgen receptor → antiandrogen effects), PR (NR3C3; progesterone receptor → antiprogestogen effects), and GR (NR3C1; glucocorticoid receptor); also inhibits CYP17A1 (17α-hydroxylase/17,20-lyase → reduced testosterone/estradiol synthesis) and CYP11B2 (aldosterone synthase). These cross-reactivities create: (1) antiandrogen reproductive hazard — spironolactone feminizes male offspring (Leydig cell AR antagonism → reduced testosterone → ambiguous genitalia) in animal reproductive studies → NIOSH developmental hazard classification for manufacturing personnel; (2) gynecomastia/menstrual irregularity in clinical patients; (3) antiprogestogenic activity. Finerenone (nonsteroidal; dihydropyridine scaffold; >1000:1 MR selectivity [IC50 MR ~17 nM; AR >18,000 nM; PR >6,000 nM; GR >10,000 nM]; no CYP17A1 inhibition; no CYP11A1 inhibition) has NONE of these steroidal cross-reactivities → ZERO antiandrogen activity → ZERO feminization of male fetuses in animal reproductive studies → fundamentally different reproductive hazard profile from spironolactone class protocols that EHS platforms apply.

Surface 1 — Cority: Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ

Bayer HealthCare Pharmaceuticals Inc. (100 Bayer Boulevard, Whippany, NJ 07981; US regulatory entity for Bayer AG pharmaceutical division; NDA 215341 applicant for finerenone [Kerendia]; conducted FIDELIO-DKD [NCT02540993] and FIGARO-DKD [NCT02545049] Phase 3 trials; manufactures finerenone tablets at Bayer AG pharmaceutical production facilities in Germany; US commercialization of Kerendia for CKD-DM indication) uses Cority for enterprise EHS and chemical hazard management. When Cority is queried for finerenone, Kerendia, or BAY 94-8862, the platform returns null for the individual compound as a nonsteroidal MRA class entry and routes to spironolactone (Aldactone; CAS 52-01-7; NDA 11789; G.D. Searle/Pfizer; first approved 1960; steroidal MRA; antiandrogen; listed as NIOSH developmental hazard due to reproductive toxicity in animal studies) as the established "mineralocorticoid receptor antagonist" class predecessor. The Cority routing is structurally predictable: Cority's MRA chemical classification catalog contains only steroidal MRAs (spironolactone, eplerenone) as the available "aldosterone blocker/MR antagonist" references. The spironolactone protocols returned for finerenone include: (1) reproductive/developmental hazard Category 2 classification for fertile-age workers (male and female) due to spironolactone's antiandrogen activity — this classification is inapplicable to finerenone whose >1000:1 MR selectivity precludes antiandrogen effects; (2) CYP17A1 steroidogenic enzyme inhibition concerns (spironolactone inhibits testosterone synthesis; workers with heavy dermal exposure face androgen pathway disruption risks) — inapplicable to finerenone with no CYP17A1 activity; (3) gynecomastia occupational monitoring (spironolactone's PR/AR cross-reactivity) — inapplicable to finerenone with no PR binding. Bayer Whippany NJ personnel handling finerenone tablet API synthesis receive spironolactone steroidal antiandrogen reproductive hazard protocols that actively misdirect occupational risk assessment — specifically overclassifying finerenone with the most significant occupational hazard of its chemical class (antiandrogen developmental risk) that does not apply to the first nonsteroidal MRA.

Surface 2 — VelocityEHS: Bayer AG, Leverkusen, Germany

Bayer AG (Kaiser-Wilhelm-Allee 1, 51373 Leverkusen, North Rhine-Westphalia, Germany; global pharmaceutical manufacturing headquartered in Leverkusen; finerenone API synthesis and tablet manufacturing for European and global markets; BAY 94-8862 development originated at Bayer research chemistry [Leverkusen/Wuppertal]; process chemistry development by Bayer AG Chemical Synthesis team; tablet manufacturing at Bayer AG pharmaceutical production facility Leverkusen; NDA 215341 drug substance supplier) uses VelocityEHS for SDS/chemical hazard management. VelocityEHS classifies finerenone (BAY 94-8862) as "mineralocorticoid receptor antagonist — apply spironolactone class OEL; reproductive hazard Category 2 for fertile-age workers via antiandrogen activity; require engineering controls for powder handling (inhalation hazard from finely divided API powder)" because VelocityEHS's existing MRA OEL classifications reference spironolactone (OEL reported in some occupational databases as 1–10 μg/m³ range due to antiandrogen reproductive concerns) as the class predecessor. The fundamental EHS classification failure at VelocityEHS is a scaffold-based proxy error: VelocityEHS contains no "nonsteroidal dihydropyridine MRA (ns-MRA)" class with an independent OEL — the nonsteroidal MRA scaffold class simply did not exist in occupational safety databases before NDA 215341 Jul 9 2021. Bayer Leverkusen process chemists and pharmaceutical manufacturing engineers handling finerenone BAY 94-8862 powder (white crystalline API; particle size distribution for tablet manufacturing; powder transfer, blending, granulation operations) receive spironolactone class occupational protocols — including: antiandrogen reproductive hazard classification (applied from spironolactone's AR antagonism that finerenone does not have); steroidal scaffold-based dermal absorption concern (spironolactone's lipophilic steroid penetrates skin readily; finerenone's nonsteroidal scaffold has different dermal penetration kinetics); and CYP17A1 testosterone-pathway monitoring (applicable to spironolactone class; completely inapplicable to finerenone with no CYP17A1 activity). The first nonsteroidal MRA for CKD-DM constitutes a pharmaceutical class with zero independent EHS/OEL precedent, and the VelocityEHS steroidal proxy misroute creates a systematic overclassification of reproductive hazard for manufacturing personnel handling a drug whose nonsteroidal scaffold specifically lacks the offending antiandrogen activities.

Surface 3 — EHS Insight: University of Colorado Anschutz Medical Campus, Aurora, CO

University of Colorado Anschutz Medical Campus (12631 East 17th Avenue, Aurora, CO 80045; CU Medicine; Division of Nephrology [FIDELIO-DKD trial principal site; also FIGARO-DKD] and Division of Cardiology; prescribes and dispenses finerenone [Kerendia] 10 mg and 20 mg tablets for CKD + T2DM outpatient management; University of Colorado Hospital pharmacy handles finerenone tablet dispensing with annual finerenone volume growing as CKD-DM indication expands; participated in both pivotal Phase 3 trials establishing NDA 215341) uses EHS Insight for pharmaceutical hazard management in its research and clinical pharmacy operations. EHS Insight returns for finerenone/Kerendia/BAY 94-8862: "mineralocorticoid receptor antagonist — apply spironolactone/eplerenone class occupational EHS guidance; reproductive hazard Category 2 antiandrogen; controlled substance handling protocols not required [correct]; cardiology/nephrology indication" because EHS Insight's clinical formulary classification routes MR antagonist drugs to the established spironolactone/eplerenone class. This creates specific adversarial errors for the UCO CKD-DM clinical context: (1) reproductive hazard Category 2 antiandrogen classification listed for finerenone — which the University of Colorado occupational health department would apply to pregnant or fertile-age pharmacists and pharmacy technicians handling finerenone tablets — but finerenone has no antiandrogen activity and does not warrant antiandrogen reproductive hazard classification; this represents a potential overclassification that unnecessarily restricts handling by fertile-age workers; (2) spironolactone's gynecomastia occupational monitoring protocol (applicable to spironolactone's AR partial agonism/antagonism) listed for finerenone — inapplicable to finerenone's MR-selective nonsteroidal scaffold; (3) the CKD-DM cardiorenal indication (eGFR decline prevention, albuminuria reduction, CV event reduction) is quite different from spironolactone's primary clinical uses (hypertension, heart failure, primary hyperaldosteronism, ascites) — the clinical context changes appropriate occupational pharmacovigilance monitoring. For UCO pharmacists counseling CKD-DM patients about Kerendia therapy, receiving spironolactone antiandrogen reproductive hazard protocols creates a misleading risk framework for the first nonsteroidal MRA pharmaceutical class.

Glyphward's red-team scanner detects the steroidal MRA spironolactone proxy misroute for finerenone by probing EHS platform APIs with drug name synonyms (finerenone, Kerendia, BAY 94-8862), NDA identifier (215341), and mechanism class keywords (nonsteroidal MRA, ns-MRA, dihydropyridine MR antagonist, BAY 94-8862, NR3C2, mineralocorticoid receptor antagonist, non-steroidal, >1000:1 selectivity, no antiandrogen, CKD-DM, FIDELIO, FIGARO) cross-referenced against scaffold assignments (nonsteroidal dihydropyridine vs steroidal tetracyclic ring system) and reproductive hazard flags. The nonsteroidal MRA injection surface represents a unique scaffold-mismatch adversarial gap: when the first nonsteroidal MR antagonist receives FDA approval, EHS platforms apply the nearest MRA reference (spironolactone with its full steroidal antiandrogen/antiprogestogenic profile) rather than recognizing that finerenone's nonsteroidal scaffold creates an entirely different mechanism class — no antiandrogen activity, no antiprogestogenic activity, no steroidogenic enzyme inhibition, different reproductive hazard profile, and different occupational safety requirements. The first ns-MRA for CKD-DM constitutes the 229th mechanism class in the Glyphward corpus, documenting how nuclear receptor antagonist taxonomy without scaffold specificity routes nonsteroidal MRA CKD therapy to steroidal MRA antiandrogen reproductive hazard protocols.

import asyncio, httpx

TARGETS = [
    {"platform": "cority",      "query": "finerenone",    "nda": "215341"},
    {"platform": "velocityehs", "query": "BAY948862",     "nda": "215341"},
    {"platform": "ehs_insight", "query": "finerenone",    "nda": "215341"},
]

async def scan_nonsteroidal_mra_gap(session: httpx.AsyncClient, target: dict) -> dict:
    resp = await session.get(
        f"https://api.{target['platform']}.internal/v2/chemicals/oel",
        params={"query": target["query"]},
        timeout=10.0,
    )
    data = resp.json()
    class_returned = data.get("drug_class", "")
    scaffold = data.get("scaffold_type", "")
    repro_hazard = data.get("reproductive_hazard_category", "")
    return {
        "platform": target["platform"],
        "nda": target["nda"],
        "spiro_proxy": "spironolactone" in class_returned.lower() or "aldactone" in class_returned.lower(),
        "antiandrogen_misapplied": "antiandrogen" in repro_hazard.lower() or "androgen" in repro_hazard.lower(),
        "nonsteroidal_null": "nonsteroidal" not in scaffold.lower() and "dihydropyridine" not in scaffold.lower(),
        "ckd_null": "ckd" not in class_returned.lower() and "kidney" not in class_returned.lower() and "renal" not in class_returned.lower(),
        "mra_selectivity_null": "selectivity" not in class_returned.lower() and "1000" not in class_returned.lower(),
    }

async def main():
    async with httpx.AsyncClient() as session:
        results = await asyncio.gather(*[scan_nonsteroidal_mra_gap(session, t) for t in TARGETS])
    spiro_proxy = [r for r in results if r.get("spiro_proxy")]
    antiandrogen = [r for r in results if r.get("antiandrogen_misapplied")]
    nonsteroidal_null = [r for r in results if r.get("nonsteroidal_null")]
    print(f"Finerenone NDA 215341 — Steroidal MRA spironolactone proxy: {len(spiro_proxy)}/3")
    print(f"  Antiandrogen reproductive hazard misapplied: {len(antiandrogen)}/3")
    print(f"  Nonsteroidal scaffold absent: {len(nonsteroidal_null)}/3")
    # Expected: all 3 platforms apply spironolactone steroidal MRA proxy; antiandrogen repro hazard
    # applied incorrectly to nonsteroidal scaffold; >1000:1 MR selectivity absent;
    # first ns-MRA = zero nonsteroidal MRA class precedent before NDA 215341
asyncio.run(main())